Jessica Okosun

Professor Jessica Okosun serves as Professor of Translational Cancer Research and Group Leader at the Centre for Haemato-Oncology, Queen Mary University of London, focusing on genetic and molecular mechanisms underlying non-Hodgkin's lymphomas to identify clinically relevant biomarkers for improved patient outcomes.

Her educational background includes an MA, MB BChir (medical degree), MRCP, FRCPath, and PhD, reflecting dual expertise in clinical medicine and laboratory research. Professional qualifications demonstrate specialization in hematology and pathology.

Research spans Bioinformatics, Cancer Genetics, Clinical Trials, Stem Cells, Blood, Leukaemia, and Lymphoma with emphasis on genomic profiling of lymphoid malignancies. Work integrates molecular analysis and translational approaches to dissect tumor heterogeneity, mutation patterns, and biomarker development for follicular lymphoma and primary CNS lymphoma.

Publication trends reveal consistent genomic focus on intra-tumor heterogeneity, recurrent mutations (e.g., RRAGC/mTORC1 pathway), and biomarker validation across lymphoma subtypes. Research bridges fundamental cancer biology with clinical applications through multicenter collaborations and clinical trial integration.

Major grant leadership includes Blood Cancer UK Transformational Award (2025-2030), Cancer Research UK-Genmab REFRACT trial (2023-2030), and Astra Zeneca-sponsored projects. Current funding portfolio spans translational research, clinical trials (OptiMATe, PRIZM+), and innovation awards totaling over £15M in active commitments.

Scientific service encompasses Cancer Research UK Clinical Research Committee, European Haematology Association Research Committee, Haematologica Associate Editorship, and Lancet Haematology International Advisory Board. Additional roles include German Cancer Aid Reviewer Committee and Lymph&Co Scientific Advisory Board.

As research group leader, she directs translational programs within the Centre for Haemato-Oncology, fostering collaborations between laboratory scientists and clinicians to accelerate biomarker-driven therapeutic advances in lymphoid malignancies.